Aethlon Receives Government and Industry Support for HIV and Hepatitis-C Trials in India

SAN DIEGO - March 28, 2005 - Aethlon Medical, Inc. (OTCBB: AEMD) announced today that it has been advised by Qualtran LLC, a contract research organization (CRO) managing clinical trials for Aethlon in India, that both the Government of India and Industry are supportive of Aethlon's upcoming HIV and Hepatitis-C trials.

Mr. Sandeep Malik, President of Qualtran, stated, "We are pleased to disclose that Aethlon has received letters of support from both the Government of India and the Confederation of Indian Industry (CII), which is India's premier business association." Mr. Malik continued, "Members of Parliament, Ashok Argal and Shripad Naik are personally supportive of Aethlon's HIV trials in India. They believe that if successful, Aethlon's technology could have a profound impact on the condition of HIV patients in India and around the world."

Mr. Malik concluded, "HIV infections in India could increase sharply if effective treatment strategies are not widely implemented. This could have devastating effects on the country's economic and social systems. Aethlon's Hemopurifier(TM) technology and forthcoming trials have been very well received by key opinion leaders in India." According to the Gates Foundation, 5.1 million individuals in India were infected with HIV in 2004, a ten-fold increase over the last decade. It is projected that the number of HIV-infected citizens in India could increase to 20-25 million by 2010. Aethlon stated that site selection for the trials is under way, and that patient enrollment should begin in the coming months.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to treat HIV/AIDS, Hepatitis-C (HCV), and pathogens that are mass casualty biological warfare candidates. Each treatment application employs the use of a proprietary technology known as the Hemopurifier(TM), which is designed to rapidly reduce the presence of infectious disease and toxins in the body. The Hemopurifier converges the established scientific principals of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. More information on Aethlon Medical and the Hemopruifier technology is available at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Contact:
Aethlon Medical, Inc.
Anne Hoversten, 858-459-7800 ext. 300
anne@aethlonmedical.com

Source: Aethlon Medical, Inc.